Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.82 |
| ▸ | CCR5 | P51681 | 3/20 | 0.82 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.39 |
| ▸ | TERT | O14746 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6503774 | 0.99 | CCR2 (0.81) | CCR2CCR5NR3C1TERTMCHR1 | |
| Hydrochloric Acid SCHEMBL6496024 | 0.99 | CCR2 (0.82) | CCR2CCR5NR3C1TERTMCHR1 | |
| Hydrochloric Acid SCHEMBL6882376 | 0.99 | CCR2 (0.81) | CCR2CCR5NR3C1TERTMCHR1 | |
| SCHEMBL18841098 | 0.90 | CCR2 (1.00) | CCR2CCR5NR3C1MCHR1 | |
| SCHEMBL6505132 | 0.86 | CCR2 (0.65) | CCR2CCR5NR3C1TERTMCHR1 | |
| SCHEMBL6495567 | 0.86 | CCR2 (0.64) | CCR2CCR5NR3C1TERTMCHR1 | |
| Hydrochloric Acid SCHEMBL6498319 | 0.86 | CCR2 (0.65) | CCR2CCR5NR3C1TERTMCHR1 | |
| SCHEMBL6502700 | 0.85 | CCR2 (0.63) | CCR2CCR5NR3C1TERTMCHR1 | |
| SCHEMBL6493795 | 0.85 | CCR2 (0.63) | CCR2CCR5NR3C1TERTMCHR1 | |
| Hydrochloric Acid SCHEMBL6496230 | 0.85 | CCR2 (0.65) | CCR2CCR5NR3C1TERTMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962926-B2 | Antagonist of MCP-1 function, and compositions and methods of use thereof | TELIK, INC. (US) | 2005-11-08 | — | — | US | claimed |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2004-10-07 | — | — | US | claimed |
| US-6962926-B2 | Antagonist of MCP-1 function, and compositions and methods of use thereof | TELIK, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198719-A1 | Antagonist of MCP-1 function, and compositions and methods of use thereof | CCR1, CCL11, CCL2 | CCR2 4/4885CCR5 9/4885NR3C1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.